Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by TCR2 Therapeutics

TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
TCR² Therapeutics Announces Pipeline Priorities for 2023
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
From TCR2 Therapeutics
Via GlobeNewswire
Tickers TCRR
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.